Mizoribine therapy in a patient with lupus nephritis: the association between mizoribine concentration and peritoneal dialysis.
We describe a 20-year-old female with systemic lupus erythematosus (SLE) who developed renal failure during continuous ambulatory peritoneal dialysis (CAPD). The patient was treated with mizoribine (MZR). MZR peak concentration was 1.8 mug/ml and was sufficient for clinical efficacy as measured by serological data. Treatment with MZR was safe and useful even while undergoing CAPD. Achieving optimal MZR blood concentration was important for treatment of SLE, even though the patient was in end-stage renal failure.
Kuroda
Takeshi
T
Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Cyuuou-ku, Niigata 951-8510, Japan. kurodat@med.niigata-u.ac.jp
Kobayashi
Daisuke
D
Sato
Hiroe
H
Oyanagi
Akihisa
A
Wada
Yoko
Y
Murakami
Syuichi
S
Nakano
Masaaki
M
Narita
Ichiei
I
D005260:Female; D006801:Humans; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors; D007166:Immunosuppressive Agents / Q000097:blood / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D008181:Lupus Nephritis / Q000150:complications / Q000628:therapy*; D010530:Peritoneal Dialysis; D012263:Ribonucleosides / Q000097:blood / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D007168:IMP Dehydrogenase